Empagliflozin Alleviates Atherosclerosis Progression by Inhibiting Inflammation and Sympathetic Activity in a Normoglycemic Mouse Model
Yihai Liu,1,2,* Mingyue Wu,1,* Biao Xu,1 Lina Kang1 1Department of Cardiology, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, 210008, Jiangsu, People’s Republic of China; 2Department of Cardiology, Affiliated Drum Tower Hospital, Clinical College of Nanjing Medica...
Guardado en:
Autores principales: | Liu Y, Wu M, Xu B, Kang L |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ba026a2cfd9b44928fce8329a5e600ac |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Empagliflozin in type 1 diabetes
por: Mathieu C, et al.
Publicado: (2019) -
Empagliflozin: a new strategy for nephroprotection in diabetes
por: Anton Ivanovich Korbut, et al.
Publicado: (2017) -
SGLT2 inhibitors and the changing landscape for treatment of diabetes
por: Liu S, et al.
Publicado: (2019) -
Cholinergic Elicitation Prevents Ventricular Remodeling via Alleviations of Myocardial Mitochondrial Injury Linked to Inflammation in Ischemia-Induced Chronic Heart Failure Rats
por: Yang Zhao, et al.
Publicado: (2021) -
Atherosclerosis Pathways are Activated in Pericoronary Adipose Tissue of Patients with Coronary Artery Disease
por: Konwerski M, et al.
Publicado: (2021)